ABT-263 (Navitoclax) 化学構造
分子量: 974.61

高品質保証

文献中の引用(35)

カスタマーフィードバック(13)

Quality Control & MSDS

製品説明

  • Compare Bcl-2 Inhibitors
    Bcl-2製品生物活性の比較
  • 研究分野

製品の説明

生物活性

製品説明 ABT-263(Navitoclax)は、 Bcl-xLBcl-2Bcl-w の強力な阻害剤で、Kiがそれぞれ ≤ 0.5 nM、≤1 nM 、≤ 1 nMです。
ターゲット

Bcl-xL

Bcl-2

Bcl-w

IC50

≤ 0.5 nM (Ki)

≤1 nM (Ki)

≤ 1 nM (Ki)[1]

In vitro試験 ABT-263 is structurally related to ABT-737; it is a disruptor of Bcl-2/Bcl-xL interactions with pro-apoptotic proteins. Overexpression of the prosurvival Bcl-2 family members is commonly associated with tumor maintenance, progression, and chemoresistance. [1] ABT-263 displays the protection afforded by overexpression of Bcl-2 or Bcl-xL with EC50 values of 60 nM and 20 nM, respectively. [1] A wide range of cellular activity is observed with ABT-263 having a 50% growth inhibition (EC50) of 110 nM against the most sensitive line (H146), whereas its activity in the least sensitive line (H82) results in an EC50 at 22 μM. All four cell lines with EC50 values of <400 nM (H146, H889, H1963, and H1417) are also highly sensitive to ABT-737, and the two most resistant lines (H1048 and H82) are similarly resistant to ABT-263. [2]
Cell Data
Cell LinesAssay TypeConcentrationIncubation TimeFormulationActivity DescriptionPMID
EoL-1-cell NY\sRZZWT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M37JWWlEPTB;MD6wNFY3QSEQvF2= NU\uN5JSW0GQR1XS
MV-4-11 MlLyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3v5ZWlEPTB;MD6wNVU5PiEQvF2= NF;5NY5USU6JRWK=
NKM-1 MmHNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NInabWNKSzVyPUCuNFE3QTlizszN NFfRSVFUSU6JRWK=
ML-2 M2PLbWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlPNTWM2OD1yLkCxPVg{KM7:TR?= M1X0VXNCVkeHUh?=
BV-173 NEXNW41Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWPiXVluUUN3ME2wMlAzOzF2IN88US=> Mnq4V2FPT0WU
RS4-11 NID2ZWdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXTJR|UxRTBwMEK1PFch|ryP MV;TRW5ITVJ?
HL-60 NHvLWVVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVLtbo96UUN3ME2wMlAzQTB6IN88US=> NXi2PJNpW0GQR1XS
KY821 NVnLVXdtT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUXGS5VqUUN3ME2wMlAzQTd3IN88US=> NHnP[IFUSU6JRWK=
ECC10 M2TQbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUfJR|UxRTBwMEO3PVIh|ryP MlO0V2FPT0WU
NCI-H720 MontS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NULJRnhTUUN3ME2wMlA1ODFzIN88US=> NIn2bI5USU6JRWK=
QIMR-WIL MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGnsSZpKSzVyPUCuNFQzQDdizszN MoHmV2FPT0WU
KG-1 NH7MWlNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUDJR|UxRTBwMES0PFYh|ryP MU\TRW5ITVJ?
TGW MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXjJR|UxRTBwMES2N|Mh|ryP M1[0VHNCVkeHUh?=
ATN-1 NWnY[3FNT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVT5O3hmUUN3ME2wMlA1PzN|IN88US=> M1vSZnNCVkeHUh?=
RH-18 MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYfJR|UxRTBwME[wOFgh|ryP MUPTRW5ITVJ?
EW-18 M2HUfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXvXbGxMUUN3ME2wMlA3QDRzIN88US=> MVTTRW5ITVJ?
NB17 Ml3aS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1jkOmlEPTB;MD6wO|EzPCEQvF2= M1y4XXNCVkeHUh?=
SK-NEP-1 M{jJd2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmCxTWM2OD1yLkC3NlE{KM7:TR?= NEjBNlBUSU6JRWK=
P12-ICHIKAWA NF:0dlZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4j6U2lEPTB;MD6wO|c4QCEQvF2= MUjTRW5ITVJ?
KARPAS-45 M1To[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXWzW|ZYUUN3ME2wMlA4QDF3IN88US=> NVP2OplPW0GQR1XS
EW-3 NXH2WFRST3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVPJR|UxRTBwMEiwOVMh|ryP NWX5[pUzW0GQR1XS
NB13 M4Lzbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVzJR|UxRTBwMEiyNFMh|ryP M4j6WHNCVkeHUh?=
NCI-H209 NHXRRXlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkfvTWM2OD1yLkC4O|A1KM7:TR?= MXjTRW5ITVJ?
NCI-H1092 MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MliwTWM2OD1yLkGwNlc2KM7:TR?= NYDiOIs4W0GQR1XS
NH-12 NFzocI5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnnCTWM2OD1yLkGwO|Q1KM7:TR?= MnP1V2FPT0WU
697 NHj6cmRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1rmU2lEPTB;MD6xNFg{QSEQvF2= NUj2[ll3W0GQR1XS
KE-37 NYi2SGdRT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NE\veoVKSzVyPUCuNVE{PyEQvF2= MW\TRW5ITVJ?
MOLT-4 MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NETmPJdKSzVyPUCuNVUyPjlizszN MUTTRW5ITVJ?
CHP-134 NFzhOZBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUHLSoZLUUN3ME2wMlE3OzB4IN88US=> M1;UUnNCVkeHUh?=
D-283MED NYfjZZpYT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWHJR|UxRTBwMUe2PFYh|ryP M2LyXXNCVkeHUh?=
LU-135 MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoXjTWM2OD1yLkG4OVUzKM7:TR?= NV\tSnMyW0GQR1XS
LU-134-A Mn7iS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlrTTWM2OD1yLkG4OlcyKM7:TR?= MXHTRW5ITVJ?
EM-2 NEW4eo9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3\DSmlEPTB;MD6xPVkyQCEQvF2= NGDYZpdUSU6JRWK=
LU-139 M2\zRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVjJR|UxRTBwMkC0PVgh|ryP NFrqXFdUSU6JRWK=
ALL-PO NHnTVndIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MljzTWM2OD1yLkKxPVg5KM7:TR?= Mk\HV2FPT0WU
NB12 NWLjepRjT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYCxW4hMUUN3ME2wMlI{OTF3IN88US=> NIHib4hUSU6JRWK=
KP-N-YN NFvXbpJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVu0TFU{UUN3ME2wMlI{PTd|IN88US=> MVLTRW5ITVJ?
BEN M1rCNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmPHTWM2OD1yLkKzPVY5KM7:TR?= NGnFWFlUSU6JRWK=
HCC1569 NI\afYlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXntRY9JUUN3ME2wMlI2OTB4IN88US=> M2HuTXNCVkeHUh?=
HuO9 Mnn4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlXJTWM2OD1yLkK2O|E2KM7:TR?= MluzV2FPT0WU
WM-115 NE[0W|lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkLnTWM2OD1yLkK3O|M5KM7:TR?= Ml\qV2FPT0WU
CCRF-CEM NFThbo1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mlj0TWM2OD1yLkOzOVI6KM7:TR?= NWTSbY1LW0GQR1XS
IST-SL1 NFrNV2ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkXHTWM2OD1yLkO1N|Q{KM7:TR?= NFOzRWZUSU6JRWK=
BE-13 NEHwXJRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3zvN2lEPTB;MD6zOlQ2QSEQvF2= M3vYfHNCVkeHUh?=
COR-L88 NWXKTFNoT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGjTRoNKSzVyPUCuN|Y2PCEQvF2= MVPTRW5ITVJ?
DOHH-2 MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4nuU2lEPTB;MD60NVAzOyEQvF2= MlXQV2FPT0WU
A704 NUL2SW94T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnS0TWM2OD1yLkSyOlch|ryP NIjMbmRUSU6JRWK=
KNS-81-FD MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVv5WXNTUUN3ME2wMlQ1ODF5IN88US=> NYrhTm9XW0GQR1XS
RPMI-8226 MmTmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXfvbm54UUN3ME2wMlQ2PjV{IN88US=> Mk\UV2FPT0WU
TGBC24TKB M4fSTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkLpTWM2OD1yLkS1O|c5KM7:TR?= MXTTRW5ITVJ?
NCI-H1304 NUHJRpNKT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGnMe4tKSzVyPUCuOFYyPTdizszN M4\HcHNCVkeHUh?=
MOLT-13 MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmXTTWM2OD1yLkS2OlE{KM7:TR?= NHiyPJhUSU6JRWK=
EW-22 MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3LiT2lEPTB;MD60OlY4OSEQvF2= Mn;XV2FPT0WU
MS-1 NG\Jc3JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3TTZWlEPTB;MD60Olk{OyEQvF2= NWHu[WVuW0GQR1XS
RMG-I MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NE\1emtKSzVyPUCuOFk1PjRizszN NVPjWGZWW0GQR1XS
NTERA-S-cl-D1 NF;oPHBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYXJR|UxRTBwNUCwNVkh|ryP MUXTRW5ITVJ?
NCI-H1048 NGfC[WxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3jXdmlEPTB;MD61NFk2OyEQvF2= MlXMV2FPT0WU
SW1417 Mn\vS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVPLdmpCUUN3ME2wMlU2PDN6IN88US=> MWfTRW5ITVJ?
DB NGTJWG5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M13hc2lEPTB;MD61O|A5KM7:TR?= NFHrflNUSU6JRWK=
MEG-01 NH73WYhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYTNd5FUUUN3ME2wMlU5OzJizszN NIC3NWtUSU6JRWK=
EW-13 MnXaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1L1e2lEPTB;MD61PFM1OSEQvF2= M1zhOXNCVkeHUh?=
LAMA-84 Ml;sS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnrlTWM2OD1yLkW5NlA4KM7:TR?= NHX3XZBUSU6JRWK=
J-RT3-T3-5 NVTQVFB5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUTBWoFwUUN3ME2wMlYxQDB6IN88US=> NG[2OnVUSU6JRWK=
MOLT-16 NGCyXVBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWOyWoFrUUN3ME2wMlY2OjZ2IN88US=> NYrPNJdTW0GQR1XS
DU-4475 MkfhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NX6wb2pjUUN3ME2wMlY2PDJ5IN88US=> M3PSWXNCVkeHUh?=
HAL-01 NHLZRnFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUjJR|UxRTBwN{K1OFkh|ryP NVLKdW9{W0GQR1XS
RD MoexS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2qxemlEPTB;MD63OVg6QSEQvF2= NFr4eIpUSU6JRWK=
OAW-28 M3nLeGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUHJR|UxRTBwN{izO{DPxE1? NEPqeoZUSU6JRWK=
HCC38 MkLBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlnqTWM2OD1yLkiwNVkh|ryP NIn6PJRUSU6JRWK=
NMC-G1 MnPIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXHJR|UxRTBwOEGxNlEh|ryP NFW2TVNUSU6JRWK=
EW-16 MlmwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2fXUGlEPTB;MD64NVMzQCEQvF2= MmfrV2FPT0WU
DU-145 NVTlcnZZT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVmzS4cxUUN3ME2wMlg6QTJ|IN88US=> NHPRVmtUSU6JRWK=
HPAF-II NFfKZnZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWfFSmo2UUN3ME2wMlkzPjJ6IN88US=> M4LxenNCVkeHUh?=
A427 M4LoSWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWfIcGVFUUN3ME2wMlk{ODJ{IN88US=> NX;XZZZEW0GQR1XS
PA-1 M{e5Wmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYnXNZR{UUN3ME2wMlk2PjR{IN88US=> Ml7NV2FPT0WU
OAW-42 M1HE[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGPiZ2lKSzVyPUCuPVYyPDZizszN Ml3SV2FPT0WU
L-428 MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVvvN41jUUN3ME2xMlAyOjVizszN Mn3hV2FPT0WU
COLO-824 M4LLZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mnz2TWM2OD1zLkCxO|A5KM7:TR?= NXz6OVk5W0GQR1XS
P30-OHK NWTN[HNpT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoXXTWM2OD1zLkC0Olg5KM7:TR?= MYjTRW5ITVJ?
NCI-H2170 NUPIZ|ZIT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NH\DbmpKSzVyPUGuNFYzOyEQvF2= MkfCV2FPT0WU
HCC2998 MljzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{\zcmlEPTB;MT6wO|E{PSEQvF2= M1HLVXNCVkeHUh?=
NB14 MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUj4UHF3UUN3ME2xMlE{PzR6IN88US=> MU\TRW5ITVJ?
TGBC1TKB M2\5cWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MorhTWM2OD1zLkG0NVUzKM7:TR?= NXPLcGhOW0GQR1XS
KP-N-YS NHzm[XJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlO0TWM2OD1zLkG2NlM3KM7:TR?= MVTTRW5ITVJ?
CAL-120 MnXMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MULJR|UxRTFwMU[0Nlkh|ryP MmG2V2FPT0WU
SBC-1 NVnQVIdzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWTHUZhWUUN3ME2xMlE6ODV|IN88US=> MmnZV2FPT0WU
C32 MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFXaTXJKSzVyPUGuNVkxQDhizszN MVfTRW5ITVJ?
HCC2157 M3jnNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIDsWlRKSzVyPUGuNVk1QTRizszN MnTWV2FPT0WU
COLO-792 M3j0T2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXTJR|UxRTFwMkCwO|Eh|ryP NVrY[lR[W0GQR1XS
ES7 NWDPSHo5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoDyTWM2OD1zLkK3PVUyKM7:TR?= MnPtV2FPT0WU
HEL MnG2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmnyTWM2OD1zLkOxNFI6KM7:TR?= NH;HcZpUSU6JRWK=
ES4 M2i1Wmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXHJR|UxRTFwM{S5PVgh|ryP NVjkVVdHW0GQR1XS
NCI-SNU-1 MnPNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYHJR|UxRTFwM{[1OVUh|ryP NX;RV2NKW0GQR1XS
MDA-MB-415 NVfvRY9CT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmX4TWM2OD1zLkO4PFUh|ryP Mm\WV2FPT0WU
NCI-H2342 NVu1bIFmT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXrJR|UxRTFwNECyOlkh|ryP NFyzbnhUSU6JRWK=
NB69 NIrjS4RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUHJR|UxRTFwNE[yO|Eh|ryP NIHJc5lUSU6JRWK=
D-247MG NGOwTJdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnvsTWM2OD1zLkWxNVIzKM7:TR?= MXHTRW5ITVJ?
SCC-4 NYnYW|NMT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{CxfmlEPTB;MT61PVg5PyEQvF2= MXfTRW5ITVJ?
HuH-7 NIfmOYdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUn1XnNzUUN3ME2xMlY4Ojl|IN88US=> Ml\3V2FPT0WU
A388 M2\UWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NH;CVWNKSzVyPUGuOlg4OjRizszN MkXvV2FPT0WU
Calu-3 M2nhXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUexUoliUUN3ME2xMlcxPjl5IN88US=> M{DFSHNCVkeHUh?=
NCI-H1648 NIXWWJRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3PidmlEPTB;MT63NVQyQCEQvF2= MWTTRW5ITVJ?
NCI-H2052 MnjtS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnO4TWM2OD1zLkeyNlAyKM7:TR?= M1XMTnNCVkeHUh?=
Ramos-2G6-4C10 MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoLITWM2OD1zLkezOlU3KM7:TR?= M1W5TXNCVkeHUh?=
DEL NXvZN3dpT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3SxemlEPTB;MT63OFY6OiEQvF2= MWTTRW5ITVJ?
SNU-423 M1j0Z2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NU\qWGtvUUN3ME2xMlc5OTV5IN88US=> MYnTRW5ITVJ?
COR-L23 MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVrvRWZDUUN3ME2xMlc6QDd2IN88US=> M3;jNXNCVkeHUh?=
OMC-1 NXnzWnB{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mo\pTWM2OD1zLki2NFE3KM7:TR?= NHS5[HhUSU6JRWK=
EW-11 NVGxRoNXT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1rGcWlEPTB;MT65OVY2PyEQvF2= NHn2dJVUSU6JRWK=
HSC-3 NHrFPYFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkjaTWM2OD1zLkm2N|Y2KM7:TR?= NFzFSnBUSU6JRWK=
MLMA NFzyO|VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NW\oeJZvUUN3ME2xMlk3Pjd5IN88US=> MXXTRW5ITVJ?
RCM-1 M3PXPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NW\WW4ZvUUN3ME2yMlAxOzl7IN88US=> NGLLe4RUSU6JRWK=
MFE-280 NHjVNYRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEG4RZJKSzVyPUKuNFI5PDhizszN M37p[nNCVkeHUh?=
ES8 NI\XPY1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{G5fGlEPTB;Mj6yOVQ4OSEQvF2= NYft[oFiW0GQR1XS
TE-11 MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVPJR|UxRTJwMkm0O|Mh|ryP MojmV2FPT0WU
HuO-3N1 Mn\QS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1PBPWlEPTB;Mj60PFc5KM7:TR?= NYr3UYI1W0GQR1XS
MHH-NB-11 NFnFcFVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWPJR|UxRTJwNUGxOVgh|ryP NFXqNGVUSU6JRWK=
TGBC11TKB MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHHpVZhKSzVyPUKuOVc3QDFizszN MmDRV2FPT0WU
HOP-92 MlmyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NF[4bJVKSzVyPUKuOVg4PDNizszN NXvhR45GW0GQR1XS
IGR-1 NIfRdYVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYTJR|UxRTJwNkKwN|Uh|ryP MlXFV2FPT0WU
GOTO MkHxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkjDTWM2OD1{Lk[1N|c4KM7:TR?= MUHTRW5ITVJ?
NCI-H1650 MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXjJR|UxRTJwN{KyNVUh|ryP NWfQfII3W0GQR1XS
NCI-H1581 NWL0U4UxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4roSGlEPTB;Mj63PVY5OSEQvF2= M2HVPHNCVkeHUh?=
NCI-H2405 MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXPhOmdMUUN3ME2yMlgzPzh{IN88US=> MXzTRW5ITVJ?
U-118-MG NF\ab4VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUTRfIpYUUN3ME2yMlk3PDlzIN88US=> M3\sdHNCVkeHUh?=
DoTc2-4510 NHjucpBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVXRS|RsUUN3ME2zMlAyPDF5IN88US=> NWG5UHBZW0GQR1XS
NCI-H596 NV;BeJYxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mo\ETWM2OD1|LkC0PVk4KM7:TR?= M3nrO3NCVkeHUh?=
MPP-89 MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIjrS3FKSzVyPUOuNFU3PjZizszN NUDYRW5XW0GQR1XS
GCIY MnrQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVLJR|UxRTNwMkC0PVEh|ryP M3LsXXNCVkeHUh?=
SW626 MoHFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MX3JR|UxRTNwMkS1OFMh|ryP MYXTRW5ITVJ?
OCI-AML2 NU[1blVYT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NF7aZW1KSzVyPUOuN|EzPzJizszN MVzTRW5ITVJ?
NBsusSR NXjrZXhxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnW0TWM2OD1|LkO0PVM5KM7:TR?= NHOxXlZUSU6JRWK=
AN3-CA NWHZco1nT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4fIcmlEPTB;Mz60OFI{QCEQvF2= NILwUHRUSU6JRWK=
EFM-19 Mlm0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUfQ[lZRUUN3ME2zMlQ5OzN7IN88US=> NELqPHZUSU6JRWK=
RVH-421 NI\DU3BIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4f1VmlEPTB;Mz61Olg4PyEQvF2= MmLoV2FPT0WU
5637 MofzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlzPTWM2OD1|Lk[xNVA{KM7:TR?= MUnTRW5ITVJ?
PANC-08-13 NIPsXWRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUDJR|UxRTNwNkO0O|Ih|ryP NFPjOZdUSU6JRWK=
H9 NGi3R|lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGHtW41KSzVyPUOuOlcyPDRizszN M4[xXXNCVkeHUh?=
KARPAS-299 MoH5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVTJR|UxRTNwNkezOlEh|ryP MoHJV2FPT0WU
TE-5 MknmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1e0dGlEPTB;Mz63NFcxQSEQvF2= MoPmV2FPT0WU
NOS-1 MmDLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVXydJk3UUN3ME2zMlc6QDN2IN88US=> NIO4UVNUSU6JRWK=
HH NVHGVY0{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmWwTWM2OD1|LkizPFY5KM7:TR?= Mn\XV2FPT0WU
769-P NWnZOpVbT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NH7OfIFKSzVyPUOuPFk2OSEQvF2= NGrPR2NUSU6JRWK=
CHP-212 MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVLUXldjUUN3ME2zMlkzPTR7IN88US=> NHewS4dUSU6JRWK=
NCI-H82 M3TxfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mn:yTWM2OD1|Lkm1PVM3KM7:TR?= NV;WTW97W0GQR1XS
Mo-T NXHsSGg1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnX2TWM2OD12LkC0N|EzKM7:TR?= NYH2VpBGW0GQR1XS
BB65-RCC MlzYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVHJR|UxRTRwMESzPVkh|ryP MmPpV2FPT0WU
SW1990 M4juT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3LaTGlEPTB;ND6wOVkxQCEQvF2= MoPBV2FPT0WU
LK-2 NHnuNVlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2L0bGlEPTB;ND6xNVI6OyEQvF2= Mmi4V2FPT0WU
ES5 NX;oTYRLT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MV3JR|UxRTRwMUO5PFUh|ryP NHK1U5lUSU6JRWK=
JVM-3 NFThWGlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3LPcWlEPTB;ND6xPFIzOiEQvF2= MYTTRW5ITVJ?
RPMI-7951 MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVnybmJHUUN3ME20MlIzPDF|IN88US=> Ml2xV2FPT0WU
Calu-6 MoDOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGfmWWpKSzVyPUSuNlc5QDFizszN NYWzOo1vW0GQR1XS
LC-2-ad M{nr[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{T1[mlEPTB;ND6yPVU3QCEQvF2= NUjucnBPW0GQR1XS
SW954 M4n4Smdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1THOWlEPTB;ND6yPVY3KM7:TR?= NV\Bfm1GW0GQR1XS
H-EMC-SS MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NH7QVJlKSzVyPUSuN|E5OzFizszN MX3TRW5ITVJ?
ES3 Mn3NS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWTJNYI4UUN3ME20MlM2PDRzIN88US=> NWnYbYxHW0GQR1XS
no-11 M33WcGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUDPRol7UUN3ME20MlM2PTV2IN88US=> NX7hT3J3W0GQR1XS
LAN-6 MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVTJR|UxRTRwNEWxPFkh|ryP NX3zSm51W0GQR1XS
FTC-133 NIXVWIFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1TWTmlEPTB;ND61N|k2KM7:TR?= MnG4V2FPT0WU
8505C MoPBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIfV[WVKSzVyPUSuOVQzOyEQvF2= MkD3V2FPT0WU
SW620 NXjSTmZCT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MY\JR|UxRTRwNUewOVch|ryP M4e1V3NCVkeHUh?=
BCPAP NYXwW3p7T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlXETWM2OD12Lk[zOFgyKM7:TR?= NF\4ZYxUSU6JRWK=
SK-LU-1 M4riNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEn4bmFKSzVyPUSuOlYxQDlizszN MV7TRW5ITVJ?
NCI-H1623 M2SwPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MknpTWM2OD12LkewNlI5KM7:TR?= MUHTRW5ITVJ?
C2BBe1 NV3V[lZ7T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEDLdlhKSzVyPUSuO|QxODhizszN NHrKcZFUSU6JRWK=
GP5d MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWrQVGJNUUN3ME20Mlc5Ozh6IN88US=> M{W1dnNCVkeHUh?=
NB6 M4LPdGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFvVNGpKSzVyPUSuPFYzODRizszN NFPtWVlUSU6JRWK=
MDA-MB-157 M4HHPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkjkTWM2OD12Lki4O|Yh|ryP M3fGU3NCVkeHUh?=
UMC-11 MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3HpTWlEPTB;ND64PFk3PCEQvF2= MofmV2FPT0WU
HCC1419 M1;GNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFvkN49KSzVyPUSuPVAxPjNizszN NITiUohUSU6JRWK=
NCI-H2029 MnnZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWDwPGRJUUN3ME20Mlk1OTh3IN88US=> NWHr[4g2W0GQR1XS
LXF-289 NUTMfHB7T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MonnTWM2OD13LkCzO|E6KM7:TR?= MX;TRW5ITVJ?
KINGS-1 M{TofGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYPJR|UxRTVwMEe3OFQh|ryP MVnTRW5ITVJ?
HD-MY-Z NEnDU2tIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFfveG1KSzVyPUWuNlM6PjlizszN M4\2fXNCVkeHUh?=
ESS-1 M4[xTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MknqTWM2OD13LkK1OVk4KM7:TR?= M4O1Z3NCVkeHUh?=
GI-1 M4C3PWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXnJR|UxRTVwMke5NlYh|ryP M{j4UHNCVkeHUh?=
RPMI-2650 M{j0Zmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFvJWllKSzVyPUWuN|YyPiEQvF2= NVj1[JpoW0GQR1XS
IA-LM MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2PheGlEPTB;NT6zPVg4OSEQvF2= NVOxW4VJW0GQR1XS
KP-4 M3HNN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmjiTWM2OD13LkS2N|M1KM7:TR?= Ml[zV2FPT0WU
G-402 Mki3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlS4TWM2OD13LkWxPFY2KM7:TR?= MnjUV2FPT0WU
OS-RC-2 MnjGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NX;LTVBIUUN3ME21MlUzPjB2IN88US=> M2KxWXNCVkeHUh?=
NCI-H1155 MmHmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NV\Ie3hoUUN3ME21MlU1QTV3IN88US=> NYrHbm5[W0GQR1XS
OE19 NFzCcm5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVLUeGxmUUN3ME21MlY5PjJ2IN88US=> MmDzV2FPT0WU
U-2-OS M{HNbGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4nPUGlEPTB;NT64PVAyOyEQvF2= NXvESGhyW0GQR1XS
SCC-15 NHH6V4xIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYDqTXpsUUN3ME21Mlk{PjZ{IN88US=> NV;oS2RnW0GQR1XS
NCI-H630 M{\oZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NI[xUVhKSzVyPUWuPVk1ODRizszN Ml:4V2FPT0WU
PFSK-1 NV\zSmJqT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1LDeGlEPTB;Nj6wOVI2QSEQvF2= NXnmUXZSW0GQR1XS
NCI-H1770 NYjkfJcxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYPJR|UxRTZwMkC4O|Qh|ryP NInIPYxUSU6JRWK=
SK-MEL-3 M{HyVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGno[IxKSzVyPU[uOFI6OTVizszN NYTqUGdmW0GQR1XS
LB1047-RCC NEjFd5lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXTJR|UxRTZwNEe2NlUh|ryP NF\ZNlVUSU6JRWK=
NCI-H446 M2nE[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MX;JR|UxRTZwNkK5NlUh|ryP MkXEV2FPT0WU
SW780 Ml[2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVSxXZBoUUN3ME22MlcxOTh3IN88US=> NX7IeG1IW0GQR1XS
NEC8 MoqxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGTuSHpKSzVyPU[uO|Y3OyEQvF2= NIHBbYtUSU6JRWK=
NOMO-1 MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYnnPG5VUUN3ME22Mlc5OTFzIN88US=> MUnTRW5ITVJ?
COLO-668 NHPnUXpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MknXTWM2OD14Lki0N|g4KM7:TR?= MXzTRW5ITVJ?
MC116 M2LycWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoHMTWM2OD14LkmzPFk4KM7:TR?= M4rzbnNCVkeHUh?=
HCC1937 MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{HS[GlEPTB;Nj65PVI2OSEQvF2= M4HxUnNCVkeHUh?=
NCI-N87 MnvVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEDk[ZRKSzVyPUeuNVkzQTNizszN NXn5d4pUW0GQR1XS
COLO-320-HSR NGnXU|dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NELoV25KSzVyPUeuNlI4OzhizszN M3LJTXNCVkeHUh?=
HCC1806 NVvZb2R5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGfyRmFKSzVyPUeuNlYxPDRizszN NYTpW2xoW0GQR1XS
OVCAR-3 M4LuVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYDJR|UxRTdwM{OwN|gh|ryP M4LhUnNCVkeHUh?=
NUGC-3 MlmwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1:2Z2lEPTB;Nz6zPVY6PCEQvF2= M3;mcXNCVkeHUh?=
SW1783 MkG1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Ml3TTWM2OD15LkSzNVc2KM7:TR?= NGDZO|VUSU6JRWK=
GCT M{T0cmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYDJR|UxRTdwNU[5NFYh|ryP MnjXV2FPT0WU
NCI-H2126 MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIDpTGxKSzVyPUeuO|M3OjVizszN NHTxTVNUSU6JRWK=
MEL-HO MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYnJR|UxRTdwN{ewOVQh|ryP MVvTRW5ITVJ?
CAPAN-1 M3;heGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3zVdWlEPTB;Nz63O|M2PyEQvF2= M3fQXXNCVkeHUh?=
SW756 NWG1T3NbT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{Cxe2lEPTB;Nz63PFM{OyEQvF2= MmmyV2FPT0WU
SKG-IIIa M{LhbWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NX;XOJlZUUN3ME23MlgyQDl{IN88US=> MUTTRW5ITVJ?
HCE-T Mo\BS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4qxSmlEPTB;Nz64O|c5OyEQvF2= M33LOXNCVkeHUh?=
Ca-Ski MknUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIfYOm1KSzVyPUeuPVk{QDNizszN NYHjTpRWW0GQR1XS
COLO-684 NYjRO3RzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2PsR2lEPTB;OD6wNVgyQCEQvF2= NICze4pUSU6JRWK=
KYSE-70 NIrVSopIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2fUfGlEPTB;OD6wO|czQSEQvF2= MWPTRW5ITVJ?
TI-73 MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmHxTWM2OD16LkK1PFUyKM7:TR?= MYfTRW5ITVJ?
BT-20 MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnfyTWM2OD16LkK2NFUzKM7:TR?= NX\q[XdFW0GQR1XS
MHH-ES-1 NFPYZVhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUHh[pJzUUN3ME24MlUyQDN2IN88US=> NFLCSXpUSU6JRWK=
TE-12 M3jVe2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnywTWM2OD16LkW5PVMyKM7:TR?= MYHTRW5ITVJ?
YH-13 NIfwXWNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1jKcmlEPTB;OD62NVAxQCEQvF2= MkHlV2FPT0WU
SF126 MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXzJR|UxRThwOEO4OlUh|ryP NWO4VZRZW0GQR1XS
J82 NXPsV5BiT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFPjfo1KSzVyPUiuPVAxOzhizszN MmflV2FPT0WU
RCC10RGB NXzHfWI4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3jxV2lEPTB;OD65PVU3OSEQvF2= MnXwV2FPT0WU
SK-UT-1 M2PXPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NI[2UmJKSzVyPUmuNFQ6PDVizszN NUXmeHZuW0GQR1XS
LB2241-RCC NYm4VXdvT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnO5TWM2OD17LkG5NVM4KM7:TR?= MWHTRW5ITVJ?
LB996-RCC MknDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MniyTWM2OD17LkG5PFkh|ryP NH7QWZhUSU6JRWK=
EPLC-272H NGDYWXlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGiyNFFKSzVyPUmuN|c3PTdizszN NFOwUlNUSU6JRWK=
CTV-1 M{jrXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{nVPGlEPTB;OT61OlU{OiEQvF2= NGj0V2xUSU6JRWK=
HSC-2 M2PSbWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4jzR2lEPTB;OT61O|U2KM7:TR?= MVjTRW5ITVJ?
SK-MEL-28 MoK4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M37zRWlEPTB;OT62NVg6OyEQvF2= NEfDbm1USU6JRWK=
MMAC-SF MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{DOSWlEPTB;OT62PFc2KM7:TR?= Ml2yV2FPT0WU
CP50-MEL-B NELDfVhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MX;JR|UxRTlwN{W3PFIh|ryP Ml;LV2FPT0WU
HT-1080 MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUXJR|UxRTlwN{e3N|kh|ryP NF6yUVlUSU6JRWK=
HEC-1 MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MU\JR|UxRTFyLkOzOVIh|ryP NGXpN2RUSU6JRWK=
AGS MlLsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NETXclhKSzVyPUGwMlM4PCEQvF2= M4HubXNCVkeHUh?=
GAMG NHnQTlJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3:2dGlEPTB;MUCuOVE3OiEQvF2= M3nVVnNCVkeHUh?=
SW48 M175dmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1fhTGlEPTB;MUCuOVE5QSEQvF2= Mme3V2FPT0WU
U031 M3fIN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXzpNG5xUUN3ME2xNE42QTB6IN88US=> M2j3NnNCVkeHUh?=
OVCAR-5 MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXPwdmxmUUN3ME2xNE43PDJ7IN88US=> Ml\YV2FPT0WU
SF295 M{DKOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWjFWIdPUUN3ME2xNE43PzB2IN88US=> M{\EZnNCVkeHUh?=
BHT-101 NIHtNI1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MY\JR|UxRTFyLkexO|ch|ryP NUnWcZJmW0GQR1XS
VMRC-RCZ NXfrVolMT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkLWTWM2OD1zMT6zNlAyKM7:TR?= MoXzV2FPT0WU
ACHN NFXx[3VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MljETWM2OD1zMT60NlEyKM7:TR?= NXfmOVVGW0GQR1XS
NCI-H526 NV\vNIo4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYXscJFbUUN3ME2xNU42ODR|IN88US=> MXzTRW5ITVJ?
MN-60 MmrjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFzVR3RKSzVyPUGxMlU{QSEQvF2= NVHn[ZhJW0GQR1XS
NCI-H2291 M4rzb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NV[xS5FoUUN3ME2xNU42PDZ4IN88US=> NUDhcGt4W0GQR1XS
SCC-25 M3m1NGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{TJPWlEPTB;MUGuO|U2PiEQvF2= M135eHNCVkeHUh?=
SK-MEL-2 M2TNV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIr2Z4RKSzVyPUGxMlc3OzdizszN M3\jfXNCVkeHUh?=
SN12C NHfQPZRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWnR[HBSUUN3ME2xNU46OzV3IN88US=> M{HyZ3NCVkeHUh?=
NCI-H69 MmfiS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYTS[IFxUUN3ME2xNk41OjN2IN88US=> NIDORYRUSU6JRWK=
ME-180 NYr1SmRrT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkHYTWM2OD1zMj63NFU1KM7:TR?= M{PwNnNCVkeHUh?=
MC-IXC M{PWPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHe3PGJKSzVyPUGyMlc2OThizszN M4G3ZXNCVkeHUh?=
NCI-H2347 Mke3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYLJR|UxRTF{Lke2NVQh|ryP MlP3V2FPT0WU
M059J MlHJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4fXd2lEPTB;MUKuO|czPyEQvF2= NHzWc5FUSU6JRWK=
A2058 MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MW\JR|UxRTF{Lki2PFEh|ryP M3K2eHNCVkeHUh?=
VA-ES-BJ MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVLJR|UxRTF{Lki3PFUh|ryP NIjpVHBUSU6JRWK=
Ca9-22 NHzPcllIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWfJR|UxRTF{Lkm0OVEh|ryP NITOZ2ZUSU6JRWK=
KNS-42 NFXCc3pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1XtRmlEPTB;MUKuPVk5PCEQvF2= NVP3dXdlW0GQR1XS
LoVo Mmi3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXfJR|UxRTF|LkKzNVMh|ryP M133THNCVkeHUh?=
AM-38 M3uw[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGnzOWNKSzVyPUGzMlI2PjZizszN NY\l[nJyW0GQR1XS
NB5 M3:xO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NITIXFJKSzVyPUGzMlM4PTJizszN NXraPFRsW0GQR1XS
L-363 MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2K3fGlEPTB;MUOuOFA{OyEQvF2= NXrJb4MyW0GQR1XS
SK-MEL-30 MlTiS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnzGTWM2OD1zND6wOlQ2KM7:TR?= Mof3V2FPT0WU
NCI-H1563 NGLQVJBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUXaO|JrUUN3ME2xOE43ODN7IN88US=> M3XKUnNCVkeHUh?=
NCI-H2228 NHLNT4JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NU\IcZg5UUN3ME2xOE43ODd5IN88US=> MlzMV2FPT0WU
MFM-223 NI\pR5ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NX3PdZptUUN3ME2xOU4yQDF|IN88US=> MmrkV2FPT0WU
LB831-BLC MkPzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4Dr[2lEPTB;MUWuNlc3PyEQvF2= MVfTRW5ITVJ?
SW872 MoXtS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkLFTWM2OD1zNT6zNFg3KM7:TR?= NXXPfVZLW0GQR1XS
NCI-H522 NV\O[mFLT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnPXTWM2OD1zNT6zN|A3KM7:TR?= MnfPV2FPT0WU
EW-1 NWLvU3FTT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1TTN2lEPTB;MUWuOVQ3OiEQvF2= NICyWVBUSU6JRWK=
HN M2DyU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIriN2lKSzVyPUG1MlU6PDJizszN M{K5dnNCVkeHUh?=
SW837 NX;aWGdoT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnH4TWM2OD1zNT63PFQ4KM7:TR?= NEPHWmJUSU6JRWK=
SCC-9 NWXOVmJsT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVexdoJLUUN3ME2xOU45OTF2IN88US=> M13EUHNCVkeHUh?=
MKN7 MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1jG[GlEPTB;MUWuPVc{OiEQvF2= M2\DdXNCVkeHUh?=
KYSE-410 MnrwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWHJR|UxRTF4LkW5NUDPxE1? NX;NNVlnW0GQR1XS
SK-N-DZ NVTFXo5sT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmjVTWM2OD1zNj62NVE3KM7:TR?= MnWzV2FPT0WU
COR-L105 MlXBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWLJR|UxRTF4Lk[1Nlgh|ryP NXL3c4g2W0GQR1XS
LB2518-MEL M1fMcGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2D6eWlEPTB;MU[uPFM5QSEQvF2= M2XzVHNCVkeHUh?=
OVCAR-4 NW\Z[VlOT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NITFOIRKSzVyPUG2Mlg5PjJizszN M3rw[3NCVkeHUh?=
TK10 NUjTRol7T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NE\iXndKSzVyPUG2Mlk1PzNizszN NUP6dWwzW0GQR1XS
KNS-62 NWTR[GpLT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mm\oTWM2OD1zNj65O|c4KM7:TR?= NHr4TYxUSU6JRWK=
RPMI-8866 NEDNTlRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGnxOpRKSzVyPUG3MlE4OzJizszN MYrTRW5ITVJ?
HuP-T4 NFnRU4NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4LLTGlEPTB;MUeuNlQ6PSEQvF2= NE\ybItUSU6JRWK=
CGTH-W-1 MoezS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIn4bpdKSzVyPUG3MlUzOTlizszN MYXTRW5ITVJ?
T-24 MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFL4V2RKSzVyPUG3MlU{PDdizszN Mn3IV2FPT0WU
HT-3 NXTEbGE{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUnJR|UxRTF5LkW5NVQh|ryP NXr4O|dDW0GQR1XS
KS-1 MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmfSTWM2OD1zNz62O|Mh|ryP NFuyW4dUSU6JRWK=
NCI-H1792 NYOzPI5ZT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3O0fWlEPTB;MUeuO|k5KM7:TR?= MYrTRW5ITVJ?
ABC-1 M4Dpemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1nGWGlEPTB;MUeuPFE1OSEQvF2= M2TI[nNCVkeHUh?=
BPH-1 NIXCRWlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEWzbZpKSzVyPUG4MlE3QDVizszN NWDZZ4w2W0GQR1XS
A431 MmjCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MY\JR|UxRTF6LkSxNlch|ryP MXfTRW5ITVJ?
T98G NWXOZZhCT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnT1TWM2OD1zOD61NVU4KM7:TR?= MXrTRW5ITVJ?
BHY NWDCXZZIT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3nWVmlEPTB;MUiuPFY6KM7:TR?= NGnzeIxUSU6JRWK=
Capan-2 Mn\kS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3jaTmlEPTB;MUiuPVA4QCEQvF2= MV;TRW5ITVJ?
MDA-MB-175-VII NGXuN|FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NH;3PJZKSzVyPUG4MlkzODlizszN NXz2OVZxW0GQR1XS
CAL-27 MkW5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NILqS5hKSzVyPUG5MlA1QDdizszN NEXqSZlUSU6JRWK=
AsPC-1 NWjrNW5wT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWDJR|UxRTF7Lki2OVch|ryP MVnTRW5ITVJ?
KU812 MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3zQXWlEPTB;MUmuPVU4OyEQvF2= NFH3dopUSU6JRWK=
NCI-H441 Mn\2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MorkTWM2OD1{MD6wNFEh|ryP MmH1V2FPT0WU
Mewo MkLPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWrJR|UxRTJyLkGyPFgh|ryP MVjTRW5ITVJ?
SK-MEL-24 NFK1OVVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIXob25KSzVyPUKwMlE1PzdizszN M4XLeXNCVkeHUh?=
NCI-H727 NX63SGs6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mom5TWM2OD1{MD6yO|A1KM7:TR?= M4nFWHNCVkeHUh?=
EKVX M4nicmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEfmT4pKSzVyPUKwMlYxPiEQvF2= MljlV2FPT0WU
RT-112 NFzJUIxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIjGVFRKSzVyPUKwMlYyOjJizszN NIHqepBUSU6JRWK=
CAMA-1 MoHFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWXJR|UxRTJyLkm4NFMh|ryP NXnKZZF1W0GQR1XS
SW900 NYGzd2NkT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1j2SWlEPTB;MkGuNFE1QSEQvF2= M2rCfXNCVkeHUh?=
NCI-H23 MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MU\JR|UxRTJzLkGyO|ch|ryP MmjKV2FPT0WU
SK-PN-DW NXnXfmx[T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmfSTWM2OD1{MT6xOlQ6KM7:TR?= M2\vTHNCVkeHUh?=
BB30-HNC M17jSWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MU\JR|UxRTJzLkK3OFUh|ryP MV7TRW5ITVJ?
VM-CUB-1 MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHfHfnFKSzVyPUKxMlM2OzZizszN M4Hye3NCVkeHUh?=
IST-MEL1 NFrxSVFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{LjZWlEPTB;MkGuN|Y6OiEQvF2= MUnTRW5ITVJ?
CTB-1 MoPmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4H1eGlEPTB;MkGuOFc2PSEQvF2= MnqyV2FPT0WU
LCLC-103H NV3NO|lHT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4LGcGlEPTB;MkKuNVU5OiEQvF2= M4TnRnNCVkeHUh?=
PANC-03-27 MnO0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVvJR|UxRTJ{LkWxOlkh|ryP NX36RnBXW0GQR1XS
HTC-C3 M{LPdmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3vBfWlEPTB;MkKuOVU2PSEQvF2= NUC2THlHW0GQR1XS
TE-8 NWL1UWdvT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NX7lcos3UUN3ME2yN{4zPTZ3IN88US=> MXrTRW5ITVJ?
NCI-H292 NHWxNYZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2j3XWlEPTB;MkWuN|U{PiEQvF2= NETEO4dUSU6JRWK=
COLO-680N MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGnPOJdKSzVyPUK1MlY{OjlizszN MXfTRW5ITVJ?
KYSE-520 NVWySZdRT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWnFWJdrUUN3ME2yOU43PDRizszN M4LhSnNCVkeHUh?=
NB10 NIX6dGhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFHSVYlKSzVyPUK2MlMyOTdizszN MVfTRW5ITVJ?
NCI-H661 NFLzfGxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVXJR|UxRTJ4LkS3NVMh|ryP MYrTRW5ITVJ?
GMS-10 NXToUYVpT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mlf2TWM2OD1{Nj64OlM5KM7:TR?= M2rKSnNCVkeHUh?=
NCI-H2122 NYTGU29JT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFXUdVRKSzVyPUK2Mlk6QThizszN M37aNnNCVkeHUh?=
OVCAR-8 M4LxVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWXINHlJUUN3ME2yO{4xPjN6IN88US=> MYjTRW5ITVJ?
DJM-1 MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVHJR|UxRTJ5LkG0OVQh|ryP NWO4NINKW0GQR1XS
UACC-893 MlHkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHzXUJdKSzVyPUK3Mlk5PzhizszN MkXaV2FPT0WU
C8166 NUi0cm1FT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGW2WXhKSzVyPUK4MlY6OzhizszN M3vnWnNCVkeHUh?=
NCI-H1693 MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIDwU2hKSzVyPUK4MlY6PzVizszN NIP3VWRUSU6JRWK=
TYK-nu NYfxc4gxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2q4OGlEPTB;M{CuNFM1PSEQvF2= NVTnWIpOW0GQR1XS
SW1710 MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkjMTWM2OD1|MD6xNlYh|ryP Ml7YV2FPT0WU
A375 NX\YVGFFT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1;WcGlEPTB;M{CuN|I1OyEQvF2= NWDVT3ZFW0GQR1XS
HMV-II NIf2V|NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{e2XGlEPTB;M{GuN|U6OiEQvF2= MnLmV2FPT0WU
NCI-H2087 NYHlcHdVT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3\vS2lEPTB;M{GuOlM2OiEQvF2= NH\6dWFUSU6JRWK=
CAL-54 M4Cwbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3rZemlEPTB;M{GuO|I1OSEQvF2= Mnz3V2FPT0WU
HCC70 MmjVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlPQTWM2OD1|Mj6xN|g4KM7:TR?= NH3vUopUSU6JRWK=
ES1 NWHXcHFqT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnW5TWM2OD1|Mj6zNFYzKM7:TR?= NVfkN3lbW0GQR1XS
NCI-H1355 MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoflTWM2OD1|Mz6yNFQh|ryP MnLVV2FPT0WU
CFPAC-1 MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIT1eYZKSzVyPUOzMlI{OzJizszN MX7TRW5ITVJ?
MKN28 MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXTEcVM4UUN3ME2zN{4{QDB7IN88US=> M2fkeXNCVkeHUh?=
HDLM-2 M1LNOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGnZeGFKSzVyPUOzMlY6OzFizszN NFrkXnZUSU6JRWK=
PANC-10-05 MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnXnTWM2OD1|ND6xNFE1KM7:TR?= MXzTRW5ITVJ?
SAS NXvHboZ3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUPnelZIUUN3ME2zOE41PTZ3IN88US=> M3XWOnNCVkeHUh?=
HCC1395 NWPDTWFYT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVzJR|UxRTN2LkexPFYh|ryP MoK3V2FPT0WU
8305C MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3jrRWlEPTB;M{WuPFQyPSEQvF2= M3XheHNCVkeHUh?=
KM12 MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoKxTWM2OD1|Nj63OVQ4KM7:TR?= NXrpbJBKW0GQR1XS
SW1116 M1nFV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1\YU2lEPTB;M{euOVk6OiEQvF2= NV\McZpEW0GQR1XS
SK-MEL-1 M2DQSWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3zTNWlEPTB;M{iuN|M5QSEQvF2= M1\VVnNCVkeHUh?=
HCC2218 MlXqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1HuR2lEPTB;M{iuOlUyQSEQvF2= NX3JOGsxW0GQR1XS
T84 M3f2Rmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MojWTWM2OD1|OD63OFA6KM7:TR?= NVf0OJQyW0GQR1XS
ETK-1 NX;sXphtT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4DUdmlEPTB;M{muNFIzKM7:TR?= MXXTRW5ITVJ?
COLO-800 M33pTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHLuS|dKSzVyPUO5MlM5PjhizszN NEftTFRUSU6JRWK=
CAL-12T NUP6eVhTT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFXySFJKSzVyPUO5MlUzQDFizszN NUTnOJlIW0GQR1XS
ACN NX7yUGQ4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NW\keG9vUUN3ME20NE41QTFzIN88US=> MUDTRW5ITVJ?
SJSA-1 MofFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnjUTWM2OD12MT6xOVk3KM7:TR?= NXfwUJFvW0GQR1XS
PSN1 MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4XQbWlEPTB;NEGuNVc1QSEQvF2= MXTTRW5ITVJ?
D-566MG M2nZNGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4\1NGlEPTB;NEGuNlA5PiEQvF2= NXi1cmw6W0GQR1XS
EGI-1 M37ybmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmjmTWM2OD12Mj60Nlgh|ryP MVvTRW5ITVJ?
A204 MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M165UWlEPTB;NEKuOlM5QCEQvF2= Ml;DV2FPT0WU
Saos-2 MlnHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmTsTWM2OD12Mj64N|Y6KM7:TR?= MmHmV2FPT0WU
SNU-C2B M1m0XGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWDJR|UxRTR|Lk[4O|gh|ryP NF;yUm5USU6JRWK=
HLE M1jNWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYXJR|UxRTR2LkC4OVYh|ryP MW\TRW5ITVJ?
SW1463 MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1jXfmlEPTB;NESuPVk4OSEQvF2= MlzrV2FPT0WU
DSH1 Mm\wS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIfLelFKSzVyPUS1MlAxOzNizszN M4rBW3NCVkeHUh?=
MCF7 MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXTJR|UxRTR3LkWwOVEh|ryP NYjzcVFFW0GQR1XS
K5 MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NInPTVJKSzVyPUS1Mlk1ODVizszN NUfBTZJqW0GQR1XS
NCI-H358 MnPWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1fCT2lEPTB;NEeuNlE2KM7:TR?= NU[yfJE1W0GQR1XS
NCI-H2030 MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYG3e5pGUUN3ME20O{4zOzd2IN88US=> MmH0V2FPT0WU
SW948 M1LmRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NETBW4tKSzVyPUS3MlQ3PCEQvF2= MXrTRW5ITVJ?
BALL-1 NUnVZVVsT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUXJR|UxRTR5Lk[xOlgh|ryP MYXTRW5ITVJ?
TE-9 NWCyWGR1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYPJR|UxRTR5Lkm1PFEh|ryP MnrGV2FPT0WU
SK-N-FI NUm0fWZ3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUHJR|UxRTR6LkCzOVgh|ryP M3;O[XNCVkeHUh?=
KALS-1 MlnoS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2LrSmlEPTB;NEiuNVI5QSEQvF2= NFq2S25USU6JRWK=
HO-1-N-1 NU\abIRiT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mlq4TWM2OD12OD63OFQ2KM7:TR?= MXHTRW5ITVJ?
NCI-H2452 MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1XNTGlEPTB;NEmuNVE2OiEQvF2= NV;3[GJUW0GQR1XS
OC-314 MnjrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NX3YenZ4UUN3ME20PU43QDN2IN88US=> M4fp[HNCVkeHUh?=

... Click to View More Cell Line Experimental Data

In vivo試験 When ABT-263 is administered at 100 mg/kg/day in the H345 xenograft model, significant antitumor efficacy is observed with 80% TGI and 20% of treated tumors indicating at least a 50% reduction in tumor volume. [2] Oral administration of ABT-263 alone causes complete tumor regressions in xenograft models of small-cell lung cancer and acute lymphoblastic leukemia. In xenograft models of aggressive B-cell lymphoma and multiple myeloma where ABT-263 displays modest or no single agent activity, it significantly enhances the efficacy of clinically relevant therapeutic regimens. [2]
臨床試験 ABT-263 is currently in Phase II clinical trial for the treatments of chronic lymphocytic leukemia.
特集

プロトコル (参考用のみ)

キナーゼアッセイ:

[1]

Affinity determination Binding affinities (Ki or IC50) of ABT-263 against different isoforms of Bcl-2 family are determined with competitive fluorescence polarization assays. The following peptide probe/protein pairs are used: f-bad (1 nM) and Bcl-xL (6 nM), f-Bax (1 nM) and Bcl-2 (10 nM), f-Bax (1 nM) and Bcl-w (40 nM), f-Noxa (2 nM) and Mcl-1 (40 nM), and f-Bax (1 nM) and Bcl-2-A1 (15 nM). Binding affinities for Bcl-xL are also determined using a time-resolved fluorescence resonance energy transfer assay. Bcl-xL (1 nM, His tagged) is mixed with 200 nM f-Bak, 1 nM Tb-labeled anti-His antibody, and ABT-263 at room temperature for 30 min. Fluorescence is measured on an Envision plate reader using a 340/35 nm excitation filter and 520/525 (f-Bak) and 495/510 nm (Tb-labeled anti-His antibody) emission filters.

細胞アッセイ:

[1]

細胞株 SCLC cell lines
濃度 0-1 μM
反応時間 48 hours
実験の流れ

Human tumor cell lines SCLC cell lines are maintained at 37 °C containing 5% CO2. SCLC cell lines are cultured in RPMI 1640 with 10% fetal bovine serum (FBS), 1% sodium pyruvate, 25 mM HEPES, 4.5 g/L glucose, and 1% penicillin/streptomycin. Leukemia and lymphoma cell lines are cultured in RPMI 1640 supplemented with 10% FBS and 1% penicillin/streptomycin. Cells (1-5×10 4) are treated by ABT-263 for 48 hours in 96-well culture plates in a final volume of 100 μL and cytotoxicity is assessed with the CellTiter Glo assay. In vitro cyto toxicity of ABT-263 is assayed.

動物実験:

[1]

動物モデル C.B.-17 scid-bg or C.B.-17 scid mice
製剤 Formulated in 10% ethanol, 30% polyethylene glycol 400, and 60% Phosal 50 PG
投薬量 100 mg/kg/d
投与方法 Administered via p.o.

Conversion of different model animals based on BSA (Value based on data from FDA Draft Guidelines)

SpeciesMouseRatRabbitGuinea pigHamsterDogMonkeyBaboon
Weight (kg)0.020.151.80.40.0810312
Body Surface Area (m2)0.0070.0250.150.050.020.50.240.6
Km factor361285201220
Animal A (mg/kg) = Animal B (mg/kg) multiplied by  Animal B Km
Animal A Km

For example, to modify the dose of resveratrol used for a mouse (22.4 mg/kg) to a dose based on the BSA for a rat, multiply 22.4 mg/kg by the Km factor for a mouse and then divide by the Km factor for a rat. This calculation results in a rat equivalent dose for resveratrol of 11.2 mg/kg.

Rat dose (mg/kg) = mouse dose (22.4 mg/kg) ×  mouse Km(3)  = 11.2 mg/kg
rat Km(6)
1

参考

化学情報

Download ABT-263 (Navitoclax) SDF
分子量 974.61
化学式

C47H55ClF3N5O6S3

CAS No. 923564-51-6
保管 2年-20℃
6月-80℃in solvent
別名 N/A
溶解度 (25°C) * In vitro DMSO 100 mg/mL (102.6 mM)
<1 mg/mL (<1 mM)
エタノール <1 mg/mL (<1 mM)
In vivo
* <1 mg/ml means slightly soluble or insoluble.
* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.
化学名 4-​[4-​[[2-​(4-​chlorophenyl)​-​5,​5-​dimethyl-​1-​cyclohexen-​1-​yl]​methyl]​-​1-​piperazinyl]​-​N-​[[4-​[[(1R)​-​3-​(4-​morpholinyl)​-​1-​[(phenylthio)​methyl]​propyl]​amino]​-​3-​[(trifluoromethyl)​sulfonyl]​phenyl]​sulfonyl]​-benzamide

カスタマーフィードバック (13)


Click to enlarge
Rating
Source , , J Clin Invest, 2014, 124(1): 117-28 . ABT-263 (Navitoclax) purchased from Selleck
Method Cell Viability Analysis
Cell Lines KP cells & A549 cells
Concentrations 300、500 nM
Incubation Time 96 h
Results KP mouse and A549 cells treated with a combination of ATN-224 and ABT-263 showed an increase in cell death compared with cells treated with ATN-224 alone.

Click to enlarge
Rating
Source , , Cell Death Differ, 2015, 10.1038/cdd.2015.73. ABT-263 (Navitoclax) purchased from Selleck
Method Cell Viability Analysis
Cell Lines NSC & Mcl-1 cells
Concentrations
Incubation Time 5 d
Results As seen with ABT-263, cells were largely resistant to compound alone but were extremely sensitive to combination with Mcl-1 silencing. In summary, the Bcl-xL inhibitors ABT-263 and WEHI-539 have an additive effect with Mcl-1 knockdown to reduce cell viabi眏Ỵ眐㠞眎膉癠 

Click to enlarge
Rating
Source Clin Cancer Res , 2010, 16, 4217-4225. ABT-263 (Navitoclax) purchased from Selleck
Method Fluorescence polarization assay
Cell Lines
Concentrations 0.1-10 μmol/L
Incubation Time 4-12 h
Results To further characterize the nature of the binding of ABT-737 and ABT-263 to albumin, we used a fluorescence polarization assay.There are two main drug-binding sites on HSA: site 1 on subdomain IIA and site 2 on subdomain IIIA.Interestingly, ABT-263 displayed a markedly higher binding affinity to site 2 on HSA-III A than did ABT-737 (Fig. A). Whereas ABT-737 showed no binding to site 1, ABT-263 also bound to site 1 on HSA-IIA with an IC50 of 145 μmol/L (positive control phenylbutazone: 49 μmol/L; ref. 18; Fig. B) . These data show that ABT-263 has a higher albumin-binding capacity than does ABT-737, thus limiting the amount of free drug that is available to interact with the intended target, BCL2.

Click to enlarge
Rating
Source Clin Cancer Res, 2010, 16, 4217-4225. ABT-263 (Navitoclax) purchased from Selleck
Method Fluorescein-dextran release assay/western blot
Cell Lines CLL cells
Concentrations 0-5 μmol/L
Incubation Time 1-2.5 h
Results One possible explanation for the reduced potency of ABT-263 compared with ABT-737 could be due to the former being inherently less potent. To investigate this possibility we compared their activities in a model biochemical system, using liposomes loaded with fluorescein-conjugated 10 kD dextran.The BCL-XL-mediated inhibition of liposome permeabilization was reversed in an a lmost identical concentration-dependent manner by both ABT-263 and ABT-737 (Fig. A). These results showed that both ABT-263 and ABT-737 targe t antiapoptotic BCL-XL with similar efficiency in this model liposome system containing only BCL2 family members but devoid of extraneous proteins. Another explanation for the lower potency of ABT-263 could be a lower plasma membrane permeability.we investigated the potential of ABT-737 and ABT-263 to induce cytochromec release from permeabilized CLL cells(Fig. B). ABT-737 was clearly more potentin inducing cytochrome c release from permeabilized cells.Taken together these results indicate that the reduced potential of ABT-263 to induce apoptosis cannot be explained solely by either differential plasma membrane permeability or by a lower potency of ABT-263 compared with ABT-737 to inhibit antiapoptotic BCL2 family members.

Click to enlarge
Rating
Source Clin Cancer Res, 2010, 16, 4217-4225. ABT-263 (Navitoclax) purchased from Selleck
Method Mitochondrial membrane potential assay/Immunoprecipitation/electron microscopy/apoptosis assays
Cell Lines CLL cells/murine embryonic fibroblasts
Concentrations 10-100 nmol/L/0.3-30 μmol/L
Incubation Time 2-48 h
Results To gain in sight into the mechanism of ABT-263-induced cell death, we asked whether ABT-263 induced activation of apoptotic signaling pathways. ABT-263 induced a rapid cleavage of caspase-3 and loss of mitochondrial membrane potential, but was a gain less potent than ABT-737 ( Fig.A).To investigate the activity of both compounds at the level of BCL2 inhibition, we immunoprecipitated BCL2 upon drug treatment and measured the levels of BAK displaced by ABT-737 and ABT-263.BAK was shown to be associated with BCL2 (Fig. B). ABT-737 (10 or 100 nmol/L) efficiently d isplaced BAK from BCL2, whereas higher concentrations of ABT-263 (100 nmol /L) were required to induce release of BAK (Fig. B).ABT-263 (100 nmol/L) induced similar ultrastructural changes to ABT-737 (10 nmol/L), including condensed chromatin, rupture of the outer mitochondrial membrane, and loss of mitochondrial matrix d ensity (Fig. C).Finally, ABT-263-induced apoptosis was compl et ely inhibited in murine embryonic fibroblasts deficient for Bax and Bak (Fig. D), suggesting that ABT-263, like ABT-737 is a specific inhibitor of BCL2 proteins.

Click to enlarge
Rating
Source Clin Cancer Res, 2010, 16, 4217-4225. ABT-263 (Navitoclax) purchased from Selleck
Method Apoptosis assays
Cell Lines CLL cells
Concentrations 1-1000 nmol/L
Incubation Time 4 h
Results In our study we identify two factors that affect the efficacy of the ABT-263: high cell density and plasma protein binding. In leukemic patients, the high circulating cell densities might contribute to the resistance of CLL cells to ABT-263 that we observed in whole blood as compared with standard cell culture (Fig. B).We also describe that the ABT-263 is extensively bound to albumin and that in the presence of albumin higher drug concentrations are required for apoptosis induction (Fig. D)

Click to enlarge
Rating
Source Clin Cancer Res, 2010, 16, 4217-4225. ABT-263 (Navitoclax) purchased from Selleck
Method Apoptosis assays
Cell Lines CLL cells
Concentrations 1-1000 nmol/L
Incubation Time 4 h
Results We compared the in vitro efficacy of two very closely related BCL2 antagon ists, ABT-737 and ABT-263. A direct comparison of the susceptibility of freshly isolated CLL cells to ABT-737 and ABT-263 in RPMI supplemented with 10% FCS revealed that both compounds induced efficient apoptosis but ABT-737 was∼4-fold more potent.

Click to enlarge
Rating
Source PLoS One, 2011, 6, e21980. ABT-263 (Navitoclax) purchased from Selleck
Method Hoechst staining/western blot
Cell Lines LH86 cells/Huh7 cells
Concentrations 0–20 μM
Incubation Time 24 h
Results The higher dose of ABT-263 (10–20 μM) treatment for 24 h induced significant DNA fragmentation and caspase 9 or 3 cleavage activation in HCC cells, whereas lower concentrations of ABT-263 (0–2.5 μM) had no apoptotic toxicity to HCC cells. These results suggest that HCC cells are relatively resistant to low doses of ABT-263.

Click to enlarge
Rating
Source PLoS One, 2011, 6, e21980. ABT-263 (Navitoclax) purchased from Selleck
Method Western blot/Hoechst staining/Apoptosis assays
Cell Lines LH86 cells
Concentrations 1 μM
Incubation Time 1-6 h
Results As shown in Figure A, the combination treatment of HCC cells with ABT-263 (1 μM) and YM-155 (1μM) for up to 6 h has no effects on the expressions of either anti-apoptotic protein Bcl-xL or pro-apoptotic proteins including Bad, Bak, and Bax. However, as expected, the presence of YM-155 significantly decreased survivin protein expression (Figure B, left third lane). Co-treatment of cells with ABT-263 (1 μM) and YM-155 (1μM) induced an even greater decrease in survivin protein expression (Figure B, right two lanes) than that of YM-155 itself did. However, we indeed observed that ABT-263 single treatment for 3 h resulted in survivin increase (Figure B). To further determine survivin inhibition plays a critical role in sensitizing ABT-263 to induce apoptosis in HCC cells, we down-regulated survivin expression in HCC cells by siRNA duplexes targeted against human survivin mRNA, and then examined the expression of survivin by Western blotting (Figure C) and apoptotic events after ABT-263 treatments. The results demonstrated that ABT-263 induced significant apoptosis in the survivin siRNA-transfected cells, but not in siRNA Random-transfected (control) cells (Figure D, E, and F).

Click to enlarge
Rating
Source PLoS One, 2011, 6, e21980. ABT-263 (Navitoclax) purchased from Selleck
Method Western blot/Hoechst staining
Cell Lines LH86 cells
Concentrations 1-2.5 μM
Incubation Time 1-24 h
Results Treatment of cells with ABT-263 (1-2.5 μM) for 1 h could result in the increase of phosphorylated ERK (p-ERK) but not ERK (Figure A). On the other hand, as shown in Figure B, ABT-263 (1 μM) administration could result in survivin expression increase. Thus, in an attempt to know if ERK-survivin activation could protect cells against ABT-263 toxicity, cells were untreated or treated with ABT-263 (1 μM), PD98059 (50 μM), or pre-treated with PD98059 (50 μM) followed by ABT-263 (1 μM). As shown in Figure C and D, blocking ERK activation with specific inhibitor PD98059 enhanced ABT-263-indcued apoptosis in HCC cells. To further determine ERK anti-apoptotic effects on ABT-263 treated HCC cells, we knocked down ERK expression through siRNA mediated gene silencing (Figure E) and then administrated ABT-263. Similar results revealed that ERK depletion sensitized ABT-263-induced apoptosis (Figure F). These results suggest the activation of ERK-survivin may render cells to be resistant to low dose ABT-263-induced apoptosis.

Click to enlarge
Rating
Source Biochem Biophys Res Commun, 2011, 408(2), 344-9. ABT-263 (Navitoclax) purchased from Selleck
Method Flow cytometry
Cell Lines MDCKII wild type cells/MDR1 cells
Concentrations 50 nM
Incubation Time 24 h
Results MDCKII cells transfected with MDR1 showed significantly less apoptosis inducedby ABT-737 (Fig. C) and ABT-263 (Fig. D) than wild type cells.

Click to enlarge
Rating
Source ABT-263 (Navitoclax) purchased from Selleck
Method Western Blotting/Co-Immunoprecipitation / Cell Death Experiments
Cell Lines Arf -null p185+ cells/ p185+ Arf-/- cells
Concentrations 0-1000nM
Incubation Time 24 h
Results As the navitoclax dose increased the amount of BCL-2 and BCL-X L immunoprecipitating with BIM decreased and there was a corresponding increase in MCL-1 protein associated with BIM (Fig. B). These data indicated that navitoclax displaced BIM from BCL-2 and BCL-XL and suggests that the liberated BIM could then interact with MCL-1 (Fig. B). As the navitoclax was increased we observed potentiation of the TKIs indicating a synergistic effect of combining navitoclax and TKI treatment (Fig. E&F).

Click to enlarge
Rating
Source ABT-263 (Navitoclax) purchased from Selleck
Method Western Blotting/Co-Immunoprecipitation / Cell Death Experiments
Cell Lines OP-1 Ph+ B-ALL cells/TOM1 Ph+ B-ALL cells/BV173 Ph+CML cells
Concentrations 0-60 nM
Incubation Time 24 h
Results As navitoclax was increased in the cultures we observed a potentiation of the TKIs to induce apoptosis. These data indicate that like our bservations in mouse BCR-ABL cell lines, combining TKIs and navitoclax in human Ph+ cell lines can also lead to enhanced activity. While MCL-1 expression is most overtly decreased in response to TKI treatment, it is possible that combining TKI and navitoclax may effect targets other than MCL-1 leading to cell death. These data suggest that combining TKIs and navitoclax may be effective in treating human Ph+ leukemia.

文献中の引用 (35)

技術サポート&よくある質問(FAQ)

ストックの作り方、阻害剤の保管する方法、細胞実験や動物実験に注意すべきな点を全部含めており、製品を取扱う時よくあった質問に対して取扱説明書でお答えいたします。

電話番号: +1-832-582-8158 Ext:3月曜日〜金曜日 9:00 AM–5:00 PM (米国中部標準時)

他の質問がある場合は、お気軽くお問合せください。

* 必須

Related Bcl-2 阻害剤

  • A-1210477

    A-1210477 is a potent and selective MCL-1 inhibitor with Ki and IC50 of 0.454 nM and 26.2 nM, respectively, >100-fold selectivity over other Bcl-2 family members.

  • MI-773 (SAR405838)

    MI-773 (SAR405838) is an orally available MDM2 antagonist with Ki of 0.88 nM. Phase 1.

  • Venetoclax (ABT-199, GDC-0199)

    Venetoclax (ABT-199, GDC-0199) is a Bcl-2-selective inhibitor with Kiof < 0.010 nM.

    Features:Re-engineered version of ABT-263 (Navitoclax).

  • ABT-737

    ABT-737は、Bcl-xL、Bcl-2とBcl-wのBH3模倣の阻害剤で、EC50 がそれぞれ78.7 nM、30.3 nM 、197.8 nMになる。

  • UMI-77

    UMI-77 is a selective Mcl-1 inhibitor with Ki of 490 nM, showing selectivity over other members of Bcl-2 family.

  • Obatoclax Mesylate (GX15-070)

    Obatoclax Mesylate (GX15-070)は Bcl-2 を抑制して、 Kiが0.22 μMになる.

    Features:Potential 1st-in-class small molecule antagonist of Bcl-2 designed to inhibit all relevant Bcl-2 family members, including Mcl-1.

  • TW-37

    TW-37は、組み換え型Bcl-2(Bcl-xLとMcl-1)への新しい非ペプチド阻害剤で、Ki がそれぞれ 0.29 μM、1.11 μM、0.26 μMです。

  • Sabutoclax

    Sabutoclax is a pan-Bcl-2 inhibitor, including Bcl-xL, Bcl-2, Mcl-1 and Bfl-1 with IC50 of 0.31 μM, 0.32 μM, 0.20 μM and 0.62 μM, respectively.

  • AT101

    AT-101は、反アポトーシスのBcl-2 の強力な阻害剤であることを知られて、模倣のBH3家族です。

最近チェックしたアイテム

Tags: ABT-263 (Navitoclax)を買う | ABT-263 (Navitoclax)供給者 | ABT-263 (Navitoclax)を購入する | ABT-263 (Navitoclax)費用 | ABT-263 (Navitoclax)生産者 | オーダーABT-263 (Navitoclax) | ABT-263 (Navitoclax)代理店
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
お問い合わせ